Tixagevimab/cilgavimab (tixagevimab and cilgavimab) is a neutralizing monoclonal antibody combination that targets the surface SARS-CoV-2 spike protein. Tixagevimab/cilgavimab is administered intravenously for the prevention of COVID-19.

Magnitude of Teratogenic Risk to Child Born After Exposure During Gestation: UNDETERMINED

Quality and Quantity of Data on Which Risk Estimate is Based: NONE

Comments: THE ANTIBODIES THAT COMPRISE TIXAGEVIMAB/CILGAVIMAB MAY BE ACTIVELY TRANSPORTED ACROSS THE PLACENTA IN LATER PREGNANCY.

Summary of Teratology Studies:

MAJOR CONGENITAL ANOMALIES

No epidemiological studies of congenital anomalies among infants born to women who were treated with tixagevimab and cilgavimab during pregnancy have been reported.

ANIMAL TERATOLOGY STUDIES

Animal teratology studies of tixagevimab and cilgavimab conducted by the manufacturer have not been published in the peer-reviewed literature.

Selected References:
(Each paper is classified as a review [R], human case report [C], human epidemiological study [E], human clinical series [S], animal study [A], or other [O].)

None available.